Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Dechra Pharmaceuticals PLC AGM Information 2018

Jun 30, 2018

4797_dva_2018-06-30_158a4d9c-5fdf-4f28-8f0f-5378ceecc60c.pdf

AGM Information

Open in viewer

Opens in your device viewer

Date: 19 October 2018

Dechra® Pharmaceuticals PLC Results of Annual General Meeting (AGM)

AGM Meeting Date: 10.30 am on 19 October 2018

Issued Share Capital at meeting date: 102,336,635

Number of shareholders in attendance: 9

All resolutions were passed on a show of hands.

Details of the proxy voting instructions lodged prior to the AGM are set out below:

Resolution (No. as noted on proxy
form)
Total For (1) Total Against Withheld (2)
No. of
votes
% of
vote
No. of votes % of
vote
No. of votes
Resolution 1:
To receive the accounts, the
Strategic Report, the Directors'
Report and the Auditor's Report
73,623,740 95.88 3,162,913 4.12 377,261
Resolution 2:
To approve the Directors'
Remuneration Report
76,045,670 98.58 1,092,914 1.42 25,330
Resolution 3:
To declare a final dividend
77,160,743 100.00 3,172 0.00 0
Resolution 4:
To re-elect William Anthony Rice
71,931,907 93.24 5,212,000 6.76 20,007
Resolution 5:
To re-elect Ian Page
76,265,790 98.84 898,039 1.16 86
Resolution 6:
To re-elect Richard Cotton
76,089,363 98.61 1,074,466 1.39 86
Resolution 7:
To re-elect Anthony Griffin
76,248,926 98.81 914,902 1.19 86
Resolution 8:
To re-elect Julian Heslop
76,471,131 99.10 692,698 0.90 86
Resolution 9:
To re-elect Ishbel Macpherson
76,540,810 99.22 603,098 0.78 20,007
Resolution 10:
To re-elect Lawson Macartney
76,643,113 99.33 520,716 0.67 86
Resolution 11:
To re-appoint
PricewaterhouseCoopers as
external auditor
of the Company
76,021,787 98.52 1,141,654 1.48 473
Resolution 12:
To authorise the Audit Committee
to determine the remuneration of
the external auditor
76,655,223 99.34 508,169 0.66 523
Resolution 13:
To authorise the Directors to allot
shares to specific limits
75,498,018 97.84 1,664,325 2.16 1,572
Resolution 14:
To disapply
the pre-emption rights
73,792,966 95.63 3,369,827 4.37 1,122
Resolution 15:
To disapply additional
pre-emption rights
73,637,601 95.43 3,523,885 4.57 2,428
Resolution 16:
To authorise the Company to
purchase
its own shares
76,382,960 99.00 773,210 1.00 7,744
Resolution 17:
To call general meetings (other
than an AGM) on not less than 14
clear days'
notice
75,446,021 97.77 1,717,894 2.23 0
Resolution 18:
(a)
To approve the rules of
the
Dechra Global Save As
You Earn Scheme
2018
(2018 SAYE Plan); and
(b)
To authorise the Directors
to adopt further plans
based on the 2018 SAYE
Plan
76,738,556 99.45 423,701 0.55 1,658

Notes

  1. Includes discretionary votes.

    1. A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "For" and "Against" a resolution.
    1. Resolutions 1 to 13 and Resolution 18 were ordinary resolutions, requiring more than 50% of shareholder votes to be "For" the resolutions.
    1. Resolutions 14 to 17 were special resolutions, requiring more than 75% of shareholder votes to be "For" the resolutions.
    1. Votes tendered in respect of 77,163,915 shares representing 75.40% of the issued share capital.

In accordance with Listing Rule 9.6.2R, a copy of the resolutions passed as special business at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm.

For further information, please contact:

Melanie Hall, Company Secretary Telephone number: 01606 814730

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information, please visit: www.dechra.com.

Trademarks

Trademarks appear throughout this document in italics. Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.